Trial Profile

A Phase 1b Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SOL 578 (Primary)
Indications Acute myeloid leukaemia; Mantle-cell lymphoma
Focus Adverse reactions
Sponsors PharmaEngine

Most Recent Events

25 Aug 2023 Acording to PharmaEngine media release, first patient has begun to receive drug administration.
17 Jul 2023 Status changed from not yet recruiting to recruiting.
14 Jun 2023 Acording to PharmaEngine media release, in December 2022, Zhiqing submitted the PEP07 phase I clinical human trial application overseas, and in March 2023, it was approved by the Australian Human Experiment Ethics Review Committee to conduct the first phase of human clinical trials.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com